Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience
International Journal of Dermatology · 2025-02 · 64 (2) · 319-324
DOI: 10.1111/ijd.17368 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Dermatology, online erschienen am 12.07.2024. Verfasst von Sara Cacciapuoti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatologic Agents, Psoriasis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 41 Literaturangaben.
Abstract (Originalsprache)
Background
Novel biologics targeting the IL23/T‐17 axis, such as tildrakizumab, have been developed to treat psoriasis. There is limited evidence on the use of tildrakizumab for the treatment of psoriasis in difficult‐to‐treat areas.
Objective
Our aim was to evaluate the short‐term efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis and with the involvement of difficult‐to‐treat areas.
Methods
A multicentric retrospective study was conducted on patients who initiated tildrakizumab between July 2022 and July 2023. Psoriasis Area and Severity Index (PASI), Psoriasis Scalp Severity Index (PSSI), Palmoplantar Psoriasis Area and Severity Index (ppPASI), and Nail Psoriasis Severity Index (NAPSI) were measured at baseline and after 16 weeks. The percentages of achieving a PASI75, PASI90, or PASI100 response were assessed. Dermatology Life Quality Index (DLQI) and Itch Visual Analog Scale (VAS) were measured simultaneously. Data about potential safety issues and adverse events were collected.
Results
A total of 76 patients were included, and 59 (77.6%) were affected by psoriasis localized to the scalp ( n = 32), palmoplantar locations ( n = 13), or nails ( n = 14). The mean PASI score decreased from 16.5 ± 9.8 at baseline to 1.9 ± 1.6 after 16 weeks. Tildrakizumab treatment resulted in the improvement of PSSI (19.9 ± 10.7 to 2.7 ± 4.2), ppPASI (15.4 ± 6.9 to 1.9 ± 2.3), and NAPSI (20.3 ± 16.9 to 7.6 ± 10.8) from baseline to 16 weeks, respectively. DLQI and Itch VAS also showed marked improvement.
Conclusions
Tildrakizumab is a valuable option for treating difficult‐to‐treat psoriasis and pruritus, with rapid onset of action.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
- UOC Dermatologia, PO G. Rosolico, AOU Policlinico "G. Rodolico-San Marco", Catania, Italy.
- UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy.
- Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy.
- UOC Dermatologia, AOU "R. Dulbecco", Ospedale 'A. Pugliese', Catanzaro, Italy.
- Section of Dermatology, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
ORCID-Profile: Sara Cacciapuoti, Luca Potestio, Giacomo Caldarola, Matteo Megna
Zitieren
APA
Cacciapuoti, S., Potestio, L., Gallo, L., Musumeci, M. L., Caldarola, G., D'Amico, D., Caudullo, F., Papaianni, V., De Simone, C., Peris, K., & Megna, M. (2025). Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience. International Journal of Dermatology, 64(2), 319-324. https://doi.org/10.1111/ijd.17368
Vancouver
Cacciapuoti S, Potestio L, Gallo L, Musumeci ML, Caldarola G, D'Amico D, et al. Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience. International Journal of Dermatology. 2025;64(2):319-324. doi:10.1111/ijd.17368
BibTeX
@article{Cacciapuoti2025,
author = {Cacciapuoti, Sara and Potestio, Luca and Gallo, Lucia and Musumeci, Maria Letizia and Caldarola, Giacomo and D'Amico, Domenico and Caudullo, Francesco and Papaianni, Valeria and De Simone, Clara and Peris, Ketty and Megna, Matteo},
title = {Short‐term efficacy of tildrakizumab on difficult‐to‐treat areas: a real‐world experience},
journal = {International Journal of Dermatology},
year = {2025},
volume = {64},
number = {2},
pages = {319--324},
doi = {10.1111/ijd.17368}
}
EUVIMED